DCT

2:26-cv-11835

Baxter Healthcare Corp v. InfoRLife SA

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: Baxter Healthcare Corp. v. InfoRLife SA, 2:26-cv-11835, D.N.J., 09/11/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey based on the Defendant's intent to market, distribute, and sell its product throughout the United States, including in New Jersey, upon receiving regulatory approval. The complaint asserts that such future acts are purposefully directed at the district and make it a foreseeable forum for litigation.
  • Core Dispute: Plaintiff alleges that Defendant's submission of a supplemental New Drug Application (sNDA) to the FDA for a generic version of Plaintiff's ready-to-use norepinephrine injection constitutes an act of patent infringement under the Hatch-Waxman Act.
  • Technical Context: The technology concerns packaged, ready-to-use formulations of norepinephrine, an oxygen-sensitive drug used to treat acute hypotension, which are designed to ensure long-term stability without requiring traditional antioxidants.
  • Key Procedural History: The lawsuit was initiated in response to a Paragraph IV certification notice letter sent by Defendant, which advised Plaintiff of Defendant's sNDA filing seeking to market a generic product prior to the expiration of the patents-in-suit. The patents are listed in the FDA's "Orange Book" as covering Plaintiff's commercial product. The complaint was filed within the 45-day statutory window, triggering a potential 30-month stay of FDA approval for the defendant's product.

Case Timeline

Date Event
2020-03-06 Priority Date for ’170 and ’494 Patents
2021-01-15 FDA approval of Baxter's 16 mcg/mL and 32 mcg/mL products
2021-09-01 Baxter launches Dextrose Norepinephrine Product
2023-11-21 FDA approval of Baxter's 64 mcg/mL product
2024-09-24 U.S. Patent No. 12,097,170 Issues
2025-05-06 U.S. Patent No. 12,290,494 Issues
2026-07-30 Defendant sends Paragraph IV Notice Letter to Plaintiff
2026-09-11 Complaint for Patent Infringement Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,097,170 - Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation

(Issued September 24, 2024)

The Invention Explained

  • Problem Addressed: The patent addresses the instability of norepinephrine, a drug used for critical hypotension, which degrades when exposed to oxygen, particularly in ready-to-use dilute solutions. Conventional approaches either provide concentrated solutions that require manual dilution—risking errors and contamination—or use antioxidants like sulfites, which can cause severe allergic reactions in some patients ('170 Patent, col. 1:40-2:51).
  • The Patented Solution: The invention is a multi-component packaging system that stabilizes a ready-to-use, antioxidant-free norepinephrine formulation. It consists of a primary container (e.g., an IV bag) holding the drug solution, which is sealed inside a secondary container or "overpouch." An oxygen scavenger is placed in the space between the two containers ('170 Patent, abstract). This scavenger absorbs oxygen that permeates the outer pouch, thereby protecting the drug from oxidative degradation without direct contact and without adding potentially allergenic antioxidants to the formulation itself ('170 Patent, col. 3:1-9; '170 Patent, col. 15:51-col. 16:14). The formulation is further stabilized by maintaining a specific pH range of 3.4 to 4.0 ('170 Patent, col. 11:32-43).
  • Technical Importance: This system enables the commercialization of a premixed, ready-to-use norepinephrine injection with a long shelf life, enhancing patient safety by eliminating the need for bedside dilution and avoiding the use of potentially allergenic sulfite antioxidants ('170 Patent, col. 5:1-24).

Key Claims at a Glance

The complaint does not identify specific asserted claims. Independent claim 1 is representative of the invention and includes the following essential elements:

  • A packaged, sealed container system for storing a ready-to-use, stable norepinephrine formulation.
  • A primary container holding the formulation, which comprises 0.015 mg/ml to 0.035 mg/ml norepinephrine, dextrose, and has a pH between 3.4 and 4.0.
  • The formulation is "free of an antioxidant."
  • A secondary container comprising a first flexible sheet with a metal foil and an opposing colored second flexible sheet.
  • An oxygen scavenger disposed between the containers and in "fluid communication" with the primary container's contents.
  • The primary container is a specific "multi-layer bag" with defined layers (polyethylene, polypropylene, polyamide).
  • The formulation must meet specific stability requirements (e.g., retain at least 90% of initial R-norepinephrine activity after 120 days at 25°C).

U.S. Patent No. 12,290,494 - Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation

(Issued May 6, 2025)

The Invention Explained

  • Problem Addressed: As a continuation of the application leading to the ’170 Patent, the ’494 Patent addresses the same technical problem of norepinephrine's oxidative degradation in ready-to-use solutions ('494 Patent, col. 1:40-2:55).
  • The Patented Solution: The solution is substantively identical to that described in the ’170 Patent: a dual-container system with an oxygen scavenger that stabilizes an antioxidant-free norepinephrine formulation maintained within a specific pH range ('494 Patent, abstract; '494 Patent, col. 3:20-32).
  • Technical Importance: The technical importance is the same as that of the '170 patent.

Key Claims at a Glance

The complaint does not identify specific asserted claims. Independent claim 1 is representative and includes the following essential elements:

  • A packaged, sealed container system for storing a ready-to-use, stable norepinephrine formulation.
  • A primary container holding the formulation, which comprises about 0.015 mg/ml to 0.035 mg/ml norepinephrine, dextrose, and has a pH between 3.4 and 4.0.
  • The formulation is "free of an antioxidant."
  • A secondary container with first and second flexible sheet layers.
  • An oxygen scavenger disposed between the containers.
  • The primary container is an "intravenous (IV) bag."
  • The formulation must meet specific stability requirements (e.g., has a dissolved oxygen level of less than 0.5 ppm after 150 days at 25°C).

III. The Accused Instrumentality

Product Identification

InfoRLife's Dextrose Norepinephrine Product, which is Norepinephrine Bitartrate in 5% Dextrose Injection, in concentrations of 16 mcg/mL, 32 mcg/mL, 64 mcg/mL, and 128 mcg/mL (Compl. ¶1).

Functionality and Market Context

The Accused Product is a generic drug for which Defendant is seeking FDA approval via an sNDA that relies on the prior approval of Plaintiff's Dextrose Norepinephrine Product (Compl. ¶1). It is intended for the same therapeutic use: treatment of severe, acute hypotension (Compl. ¶3). The complaint alleges that, upon approval, it will be marketed as a competing product to Plaintiff's own offering (Compl. ¶42). The complaint does not provide any technical details about the Accused Product's formulation or packaging system. No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint makes general allegations that the submission of the sNDA for the Accused Product infringes one or more claims of the patents-in-suit (Compl. ¶56; Compl. ¶65), but it does not provide specific factual allegations or claim charts mapping elements of the Accused Product to the limitations of any asserted claim. Therefore, a detailed claim chart summary cannot be constructed from the provided documents.

  • Identified Points of Contention:
    • Scope Questions: The dispute will likely focus on whether the defendant's product, as detailed in its confidential sNDA, meets the specific formulation and packaging limitations of the claims. Key questions include: Does the defendant's formulation fall within the claimed pH range of 3.4 to 4.0 and the claimed concentration ranges? Does the defendant's product contain any substance that could be construed as an "antioxidant," thereby avoiding the "free of an antioxidant" limitation?
    • Technical Questions: A factual dispute may arise over the specific structure of the defendant's packaging. For the ’170 Patent, a key question is whether the defendant's primary container is a "multi-layer bag" with the claimed polyethylene, polypropylene, and polyamide layers. For both patents, a question is whether the defendant's system includes an "oxygen scavenger" that is in "fluid communication" with the drug formulation in the manner described by the patents. The stability and dissolved oxygen level requirements in the claims also present factual hurdles that must be proven with data from the defendant's sNDA.

V. Key Claim Terms for Construction

  • "free of an antioxidant" ('170 Patent, claim 1; '494 Patent, claim 1)

    • Context and Importance: This negative limitation is central to the invention's purpose of avoiding sulfite-based allergens. The definition of this term is critical because if the defendant’s formulation contains any compound that possesses antioxidant properties—even if it is not a traditional preservative—it may be able to argue non-infringement.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation (Plaintiff-favored): The specification lists specific antioxidants to be excluded, such as "sodium sulfite, sodium bisulfite, sodium metabisulfite, ascorbic acid, cysteine" ('170 Patent, col. 6:20-25). A plaintiff may argue the term should be construed to mean free of these or other similar, intentionally-added parenteral antioxidants.
      • Evidence for a Narrower Interpretation (Defendant-favored): The patents state that "an antioxidant is not added to the norepinephrine formulations" ('170 Patent, col. 12:55-56). A defendant may argue that the plain meaning implies an absolute absence of any substance with antioxidant properties, regardless of its primary function or whether it was one of the enumerated examples.

  • "primary container is a multi-layer bag" ('170 Patent, claim 1)

    • Context and Importance: This term, present in the '170 Patent's independent claim, is significantly more specific than the corresponding term "intravenous (IV) bag" in the '494 Patent. Practitioners may focus on this term because if the defendant's container does not have the exact layered structure recited in claim 1 of the '170 Patent, it may avoid infringement of that patent, shifting the dispute to the potentially broader claims of the '494 Patent.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: A party might argue that "multi-layer bag" should not be strictly limited to the exact embodiments shown, but rather to any bag with distinct functional layers.
      • Evidence for a Narrower Interpretation: Claim 1 of the '170 Patent itself defines the term by explicitly reciting "a third flexible sheet layer of low-density polyethylene, an opposing fourth flexible sheet layer of polypropylene, a middle polyamide layer" ('170 Patent, claim 1). This language provides strong evidence that the term is strictly limited to a bag possessing these three specific types of layers.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges inducement and contributory infringement based on the filing of the sNDA, which seeks approval to market and sell the product for the patented use (Compl. ¶¶56, 65). Post-approval, the product's labeling and instructions for administration would serve as the primary evidence for inducing infringement by healthcare providers.
  • Willful Infringement: Willfulness is alleged based on the Defendant's knowledge of the patents, which is evidenced by its Paragraph IV certification letter (Compl. ¶¶58; Compl. ¶67). The complaint asserts that the Defendant acted without a reasonable basis for believing it would not be liable for infringement, thereby rendering the case "exceptional" under 35 U.S.C. § 285 (Compl. ¶¶58; Compl. ¶67).

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of definitional scope: can the negative limitation "free of an antioxidant" be construed to mean the absolute absence of any substance with antioxidant properties, or is it limited to a class of conventional, intentionally-added antioxidants? The answer to this question may determine whether the defendant's formulation infringes.
  • The case will also turn on a key evidentiary question: do the specific materials, formulation (pH, excipients), and structural components of the defendant's product, as disclosed in its confidential sNDA, fall within the precise boundaries of the asserted claims? This includes meeting the specific multi-layer bag structure of the ’170 Patent and the stability metrics recited in both patents.
  • Finally, a central strategic question will be the divergence in patent scope: if the defendant's product is found not to infringe the narrower claims of the ’170 Patent (e.g., by using a different bag structure), does it still infringe the seemingly broader claims of the related ’494 Patent, which more generically claim an "intravenous (IV) bag"?